Tashkent, Uzbekistan (UzDaily.com) - Minister of Innovative Development Ibrokhim Abdurakhmonov held an online meeting with representatives of the Shanghai Institute of Matter of the Chinese Academy of Sciences, the Xinjiang Institute of Physics and Chemical Technology, the Chinese-Uzbek Medical Technology Park.

During the meeting, information was given about the drug VV116 ("Remindevir") against the COVID-19 virus, developed by the Shanghai Institute of Matter. Professor Shen Jingshan from the Shanghai Institute of Matter gave a presentation on the chemical and medical properties of this drug, during which they exchanged views on the effectiveness of the drug. Remindevir, developed by Chinese scientists, is a new form of Remdesivir that is currently injectable, has low side effects and will be available in pill form. Currently, the drug is undergoing clinical trials, and upon completion of the research, it is planned to manufacture it in the Navoi Free Economic Zone at the plant for the synthesis of pharmaceutical substances, which will be built in conjunction with the Shanghai Institute of Pharmacology.

“The pharmaceutical plant, the construction of which is planned in Karmana district of Navoi region, will become the first enterprise in Uzbekistan that will carry out the chemical synthesis of drug substances,” said Ibrokhim Abdurakhmonov, Minister of Innovative Development. - There are many talented chemists in Uzbekistan who have so far carried out the synthesis of substances only in the laboratories of research institutes, but the synthesis of these substances has not been brought to an industrial level. The creation of the plant will allow to receive capital from science, create new jobs, conditions for the production of competitive high-tech products.

During the meeting, the parties exchanged views on accelerating the implementation of the project to create an Uzbek-Chinese medical technology park for the synthesis of medicines in Navoi region.